Recurrent ovarian cancer: QoL is a significant prognosticator in the heavily treated patient

  • Roncolato FT & al.
  • Gynecol Oncol
  • 10 Dec 2019

  • curated by Deepa Koli
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Health-related QoL at baseline is a significant predictor of PFS and OS in women with potentially platinum-sensitive recurrent ovarian cancer (PPSROC; platinum-free interval >6 months) who have had 3 or more lines of chemotherapy.

Why this matters

  • In the heavily treated patient, identification of the prognostic factors could help clinicians to decide whether supportive care could be better than chemotherapy.   

Study design

  • A gynecological cancer intergroup (GCIG) symptom benefit, prospective cohort study of 378 adult women with PPSROC≥3 chemotherapy who completed health-related QoL questionnaires.
  • Funding: None disclosed.

Key results

  • 45 (12%) participants stopped using chemotherapy ≤8 weeks:
    • Median PFS, 1.6 (95% CI, 1.2-1.7) months.
    • Median OS, 3.4 (95% CI, 1.7-7.2) months.
  • Social function was a statistically significant factor for predicting PFS: aHR: 1.30 (P=.030).
  • Health-related QoL domains associated (aHRs) with OS included (P<.041 style="list-style-type:circle;">
  • Physical function: 1.61 (P=.011).
  • Role function: 1.45 (P=.041).
  • Cognitive function: 1.47 (P=.026).
  • Social function: 1.83 (P<.001>
  • No significant health-related QoL predictors for stopping chemotherapy early (within 8 weeks) were observed.  
  • Limitations

    • Observational study design.
    • Self-reported data.